Easton Pharmaceuticals, XL-protein deal

The companies partnered to develop and commercialize biologics against an undisclosed Easton ophthalmology target using XL-protein’s PASylation half-life extension technology. XL-protein will conduct early preclinical development, and Easton will conduct further development. Easton will have exclusive rights to commercialize the products in China and will have options to obtain worldwide rights to the compounds and for additional indications. ...